Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

part 2 > Gynae problems > Flashcards

Gynae problems Flashcards

1
Q

PMB: overall risk of underlying endometrial Ca

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

PMB >80yo: risk of underlying endometrial ca

A

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

PMB<50yo: risk of underlying endometrial ca

A

1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PMB + obesity: risk of underlying endometrial ca

A

18%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PMB + diabetes: risk of underlying endometrial ca

A

21%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PMB + obesity + diabetes: risk of underlying endometrial ca

A

29%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

most common cause of PMB

A

atrophic endometritis and vaginitis (60-80%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

progression rate of EH without atypia (overall)

A

<5% over 20 y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

progression rate of SIMPLE EH without atypia

A

1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

progression rate of COMPLEX EH without atypia

A

4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

progression rate of EH WITH ATYPIA

A

27% over 20y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

prevalence of atypia within endometrial polyp

A

0.8% -1.2% in asymptomatic patient (up to 2%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

prevalence of malignancy within endometrial polyps

A

3.1% in symptomatic patients (only 0.3% in asymptomatic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

EH without atypia: rate of REGRESSION

A

75-80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

vaginal discharge following UAE

A

20-30%

16% at 12/12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

expulsion of fibroid material following UAE

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

endometritis following UAE

A

0.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

change in sexual fxn following UAE

A

worse 10%
improved 26%
unchanged in most

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

early ovarian failure following UAE

A

1-2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

UAE is associated with higher rates of ____ intrapartum

A

C/S

PPH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

GnRH for fibroids: % reduction in size at 12 weeks

A

36%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

GnRH for fibroids: fibroid size returned to pre-treatment within ____

A

4-6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

pre-test probability of Endometrial ca in TVS ET<4mm

A

<1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

systemic HRT benefits

A 
sx control
BMD maintenance
decreased CAD and alzheimers if started early
decreased colorectal ca
decreased T2DM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

systemic HRT risks

A 
endometrial ca
VTE (2-3x background risk)
CHD - if started >60yo
stroke
Breast ca - slight increase after 5y
small but not significant increase ovarian ca
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

combined systemic HRT: impact on breast ca risk

A

increase by 4/1000 cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

oestrogen only systemic HRT: impact on breast ca risk

A

decrease by 4/1000 cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

prevalence of PMS

A

40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

severe PMS incidence

A

5-8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

first line management PMS

A

Exercise
CBT
Vit B6
COCP (continuous or cyclical - ideally containing drosperinelone eg Yasmin)
Continuous or luteal phase low dose SSRI (eg. citalopram 10mg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Second line management PMS

A

estradiol patches 100mcg + micronised progesterone day 17-28 (or LNG-IUS)
Higher dose SSRIs (20-40mg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

third line management PMS

A

GnRH analogues + add back HRT

    • reserve for most severe sx
  • *need DEXA annual
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

post menopausal simple cyst <5cm: at 2y, what proportion disappear

A

53%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

post menopausal simple cyst <5cm: at 2y, what proportion remain static

A

28%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

post menopausal simple cyst <5cm: at 2y, what proportion increase in size

A

11%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

post menopausal simple cyst <5cm: at 2y, what proportion decrease in size

A

3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

post menopausal simple cyst <5cm: at 2y, what proportion fluctuate

A

6%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

post menopausal simple cyst <5cm, asymptomatic, unilateral, unilocular, normal Ca125 – MANAGEMENT? Risk of malignancy?

A

Ca125 and Repeat USS in 4-6/12 x 1y
Discharge at 1y if no change

Risk of malignancy <1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

RMI<25 – % risk malignancy?

A

<3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

RMI 25-250 – % risk malignancy?

A

20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

RMI >250 – % risk malignancy?

A

75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

pre-menopause ovarian cyst - lifetime risk

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

pre-menopause ovarian cyst - % borderline appearing as simple cyst

A

20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

pre-menopause ovarian cyst: management of asymptomatic simple cyst <5cm

A

discharge, likely physiological

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

pre-menopause ovarian cyst: management of asymptomatic simple cyst 5-7cm

A

year USS +/- MRI +/- surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

pre-menopause ovarian cyst: management of asymptomatic simple cyst >7cm

A

MRI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

risk of recurrence ovarian cyst if aspirated

A

53-84%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

risk of chemical peritonitis if dermoid spillage

A

0.2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

incidence of malignant symptomatic cyst (pre-menopause)

A

1/1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

differentiated VIN associated with ____

A

lichen sclerosus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

undifferentiated VIN associated with ____

A

HPV and smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

rate of re-operation for recurrent menstrual symptoms following endometrial ablation

A

20-27%

Lower rates with 2nd gen techniques, but not statistically significant

Saraswat, L, Cooper, K. Surgical management of heavy menstrual bleeding: part 1. The Obstetrician & Gynaecologist 2017; doi:10.1111/tog.12333 19: 37– 45.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

rate of hysterectomy for recurrent menstrual symptoms following endometrial ablation

A

14-20% by 5y

Majority will occur within 2y

Saraswat, L, Cooper, K. Surgical management of heavy menstrual bleeding: part 1. The Obstetrician & Gynaecologist 2017; doi:10.1111/tog.12333 19: 37– 45.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

re-intervention rate for UAE at 3y

A

15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

hysterectomy rate after UAE at 5y

A

28%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

incidence of OAB

A

13-16%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

proportion requiring additional management after salpingotomy

A

1/5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

overall survival cervical cancer

A

65% (65-70%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

cervical cancer stage I survival

A

95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

cervical cancer stage IV survical

61
Q

SCC accounts for ___% of all cervical ca

62
Q

adenoma accounts for ___% of all cervical ca

63
Q

action of ullipristal acetate on fibroids

A

induces apoptosis and inhibits proliferation

  • reduce menstrual loss in over 90% of patients after 13 weeks of treatment with either 5 or 10 mg daily.
  • 75% achieve amenorrhoea within 10 days .
  • The median change in fibroid volume is approximately 40–50% after 13 weeks of treatment
  • reduction is maintained for at least 6 months after stopping
64
Q

pNK cells

A

CD56 dim/ CD16+

65
Q

uNK cells

A

CD56 bright/CD16-

makes up >30% of stroma during secretory phase

66
Q

clinically insignificant post void volume

67
Q

chlamydia isolated in what % of TOA

68
Q

raised AFP, normal hCG, ovarian mass in young woman

A

endodermal sinus tumor

69
Q

bilateral multi cystic enlargement, normal AFP and hCG, raised Ca125, postmenopausal woman

A

mucinous cystadenoma

70
Q

action of bisphosphonate

A

decreased bone resorption by inhibition of osteoclasts and slowing bone remodelling cycle

71
Q

what neurotransmitters are associated with PMS

A

GABA and serotonin

72
Q

raloxifene: action on endometrium

A

antagonist

selective estrogen receptor modulator

73
Q

raloxifene: action on tissue/bone

A

agonist

selective estrogen receptor modulator

74
Q

raloxifene: action on breast

A

antagonist

selective estrogen receptor modulator

75
Q

what % of patients with chronic pelvic pain have IBS symptoms

76
Q

incidence of nerve entrapment after c/s

77
Q

incidence of chronic pelvic pain

78
Q

prevalence of endometriosis in women of reproductive age

79
Q

type I FGM

A

partial or total removal of clitoris and/or prepuce (clitoridectomy)

80
Q

type II FGM

A

partial or total removal of the clitoris and labia minor, with/without excision of labia majora (excision)

81
Q

type III FGM

A

narrowing of the vaginal orifice with creation of a covering seal by cutting and apposition of labia, with or without excision of clitoris (infibulation)

82
Q

type IV FGM

A

all other harmful procedures for non-medical purposes, including pricking, piercing, incising, scraping, cauterizing

83
Q

how many children at risk of FGM each year

84
Q

pathognomic feature of lichen sclerosus

A

hyalinization of upper dermis

85
Q

most common presenting symptom of cesarean niche

A

postmenstrual spotting, 30%

86
Q

niche defined as depth of?

A

> 2mm, excluding endometrium

87
Q

management options for c/s niche

A

hormonal treatment; LNG-IUS; ablation;
hysteroscopic resection of distal ridge;
laparoscopic niche repair under hysteroscopic guidance

88
Q

pregnancy post ablation

89
Q

overall satisfaction rate of second generation ablations

90
Q

expected amenorrhea rate after second generation ablation

91
Q

overall complication rate first gen ablation

92
Q

highest complication after first gen ablation

A

hemorrhage, 3%

1.2% in second gen

93
Q

highest complication after second gen ablation

A

endometritis, 2%

1.4% in first gen

94
Q

lowest complication after first gen ablation

A

cervical lacerations, 0.2%

1.1% in second gen

95
Q

lowest complication after second gen ablation

A

hematometra, 0.7%

2.4% in first gen

96
Q

top three complications in first gen ablation

A

hemorrhage 3%, hematometra 2.4%, endometritis 1.4%

97
Q

top three complication in second gen ablation

A

endometritis 2%, hemorrhage 1.2%, cervical lacerations 1.1%

98
Q

highest overall ablation complication rate

A

hemorrhage, 3% - first gen

99
Q

perforation rates with endometrial ablation, 1st ve 2nd gen

A

1.3% vs 0.3%

100
Q

complication rate for repeat ablation

A

2x as high

101
Q

success rate for repeat ablation

102
Q

lifetime risk of fibroids for white women

103
Q

lifetime risk of fibroids for black women

104
Q

risk of dissemination of malignancy with morcellation of fibroid

A

1:350, as reported by FDA

105
Q

what % of women are symptomatic with fibroids

106
Q

relative CI to UAE

A
  1. solitary fibroids measuring >10cm,

2. multifibroid uterus >20 week size

107
Q

relative CI to MRgFUS

A
  1. concomitant adenomyosis,
  2. > 10cm fibroids,
  3. submucosal fibroids,
  4. > 5 fibroids,
  5. anterior wall incisional scars,
  6. possible damage to bladder and bowel
108
Q

risk of leiomyosarcoma aged 40-44

109
Q

risk of leiomyosarcoma aged 50-54

110
Q

risk of leiomyosarcoma aged <30

111
Q

risk of leiomyosarcoma aged 75-79

A

up to 1/100

112
Q

conversion rate from laparoscopic to open myomectomy

113
Q

risk of emergency hysterectomy during laparoscopic myomectomy

114
Q

approximate rate of overall complications of laparoscopic myomectomy

115
Q

major complication rate of laparoscopic myomectomy

116
Q

missed dx of leiomyosarcoma due to morcellation

117
Q

approximate risk of uterine rupture following laparoscopic myomectomy

118
Q

% of PMB caused by endometrial/cervical polyps

119
Q

% of PMB caused by EH

120
Q

% of PMB caused by EC

121
Q

% of PMB caused by exogenous estrogens

122
Q

% of PMB caused by atrophic vaginitis/endometritis

123
Q

co-existing cervical and endometrial polyps at presentation

124
Q

improvement in PMS after GnRH

125
Q

most common location of transverse vaginal septums

A

upper vagina

126
Q

most common symptoms of peritoneal endometriosis

A 
dysmenorrhea 62%;
chronic pelvic pain 57%;
deep dyspareunia 55%;
cyclical intestinal complaints 48%;
infertility 40%
127
Q

postablation tubal sterilization syndrome

A

cyclical unilateral/bilateral pelvic pain + vaginal spotting

128
Q

most common cause of hyperandrogenism in postmenopausal women

A

ovarian hyperthecosis

129
Q

PCOS waist circumference: ideal vs high risk

A

<80, vs >87cm

130
Q

prevalence of PCOS

131
Q

% of population found to have polycystic ovaries

132
Q

biochemical abnormalities in PCOS

A 
raised androgens;
raised LH;
raised FAI;
raised AMH;
normal FSH
133
Q

PCOS genetic component - % in first degree relatives

134
Q

in PCOS women with normal glucose tolerance, what proportion developed IGT in 6y?

135
Q

in PCOS women with normal glucose tolerance, what proportion developed T2DM in 6y?

136
Q

in PCOS women with impaired glucose tolerance, what proportion developed T2DM

137
Q

% of teenagers with anovulatory cycles

138
Q

how long to wait before PCOS diagnosis in teenagers

A

2 years after menarche, should have all three criteria

139
Q

testosterone level at which to further investigate

140
Q

in what % of pts does clomiphene induce ovulation (PCOS)

141
Q

what % of pts will achieve pregnancy within 6 ovulatory cycles of clomifene therapy

142
Q

hypersecretion of LH found in what % of PCOS women

A

40%
- associated with reduced chance of conception and increased risk of miscarriage;
most often in slim women

143
Q

USS diagnosis of PCO

A

> 12 follicles, 2-9mm in diameter, and/or ovarian volume >10cm3

144
Q

risk of multiple pregnancy with clomifene

145
Q

risk of multiple pregnancy with GnRH (PCOS)

146
Q

UAE re-intervention rate at 3 years

A

15% (10% hysterectomy, 3% myomectomy, 2% repeat UAE)

147
Q

UAE hysterectomy rate at 5y

148
Q

UAE improvement rate

A

83-84% at 6 and 24 months

149
Q

UAE fibroid volume reduction

part 2 (21 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions